Table 1.

Baseline Characteristics of 193 patients with Cryptococcal Disease by site of involvement (Other Extrapulmonary compared with Central Nervous System Disease) 2002–2017.

Variable	CNS N=143(%)	OECD N=50 (%)	p
Age (±SD)	48.1(15.1)	46.1(15.9)	0.4
Male	96 (67.1)	38 (76)	0.2
White	69 (48.3)	24 (48)	0.9
Presenting Symptoms
Fever	98 (68.5)	29 (58)	0.2
Fatigue	118 (82.5)	37 (74)	0.2
Neck stiffness	52 (36.4)	2 (4)	<0.001
Headache	103 (72)	18 (36)	<0.001
AMS	87 (60.8)	9 (18)	<0.001
Visual changes	15 (10.5)	2 (4)	0.2
Weight loss	40 (28)	10 (20)	0.3
CN Palsy	5 (3.5)	1 (2)	0.6
Cough	12 (8.4)	17 (34)	<0.001
Dyspnea	10 (7)	19 (38)	<0.001
Time to Diagnosis from hospitalization	1 (0–3.25)	2 (1–4)	0.32
Time to diagnosis from symptom onset	12.5 (6–24)	21 (5.75–41)	0.09
Underlying condition
Non-HIV, non- transplant (%)	61 (42.7)	17 (34)	0.3
On immunosuppressive therapy	39 (27.2)	11 (22)	0.42
Immunocompetent	22 (15.4)	6 (12)	0.6
HIV/AIDS	69 (48.3)	25 (50)	0.8
Median CD4 at CD diagnosis (IQR)	21 (6–42)	29 (8–57)	0.02
Any Transplant	13 (9.1)	8 (16)	0.2
Diabetes Mellitus	15 (11)	9 (18)	0.2
ESLD	18 (12.6)	4 (8)	0.4
ESRD	9 (6.3)	5 (10)	0.4
Solid organ CA	13 (9.1)	9 (18)	0.08
Hematological CA	13 (9.1)	5 (10)	0.8
Microbiological Data
Serum CrAg positivity	87 (89.7)	43 (89.6)	0.9
0	10 (10.3)	5 (10.4)	<0.001
1:2 – 1:8	6 (6.2)	8 (9.5)
1:16–1:512	40 (41.2)	31 (64.6)
≥1:1024	41 (42.3)	4 (8.3)

CSN, Central Nervous System; AMS; altered mental status, OECD, Other Extrapulmonary Cryptococcal Disease; ESLD, End stage Liver Disease; ESRD, End stage Renal Disease; CA, Cancer; HIV/AIDS Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome; CrAg, Cryptococcal Antigen; CD Cryptococcal Disease.